STOCK TITAN

Polyrizon Ltd. (PLRZ) Stock News

PLRZ NASDAQ

Polyrizon Ltd. (Nasdaq: PLRZ) generates news as a development-stage biotechnology company focused on intranasal hydrogels and barrier-forming nasal sprays. Company announcements highlight progress across its Capture and Contain™ (C&C) and Trap & Target™ (T&T) platforms, including updates on allergy, viral exposure reduction, and intranasal drug delivery programs.

Readers following Polyrizon news can expect coverage of preclinical study results, regulatory interactions, and product branding milestones. Recent press releases describe positive in-vitro data for PL-14 Allergy Blocker, including allergen-blocking performance compared with a standard comparator, and the completion of a branding process that will see PL-14 marketed as NASARIX™. Other updates focus on PL-16 Viral Blocker, a non-pharmacological intranasal hydrogel spray designed to form a temporary physical barrier on the nasal mucosa, with reported preclinical evidence of protection against certain respiratory viruses.

Polyrizon also reports on the advancement of its intranasal naloxone hydrogel within the Trap & Target™ platform. News items detail mucoadhesion and permeation studies comparing the formulation to a marketed intranasal naloxone product, as well as broader commentary on the potential role of enhanced mucosal residence time in emergency opioid overdose reversal.

In addition to R&D and regulatory milestones, Polyrizon’s news flow includes strategic and corporate developments. The company has disclosed plans to explore revenue-generating investment opportunities in sectors such as defense, aviation, artificial intelligence, and real assets, alongside continued focus on its core medical pipeline. Investors and observers can use this news stream to monitor scientific progress, FDA-related steps such as pre-submission meetings and Pre-Request for Designation filings, capital structure actions like reverse share splits, and broader strategic decisions that may influence the PLRZ stock story over time.

Rhea-AI Summary

Polyrizon (Nasdaq: PLRZ) has adopted a limited-duration shareholder rights plan designed to discourage unapproved accumulations of its ordinary shares. The unanimously approved plan became effective November 9, 2026, and expires November 8, 2027. Polyrizon says it aims to protect shareholders against control acquisitions without appropriate compensation; it was not adopted in response to a specific takeover threat.

The company will issue one right per ordinary share outstanding at the close of business November 19, 2026. Rights generally become exercisable following an unapproved acquisition of 10% or more beneficial ownership. Eligible holders, excluding the acquirer, could then buy one ordinary share per right for $0.001. The board may alternatively exchange one share per eligible right after the threshold is reached. The plan remains effective pending shareholder ratification but terminates immediately if shareholders reject it.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
none
-
Rhea-AI Summary

Polyrizon (PLRZ) completed enrollment and randomization of all 120 planned participants in its U.S. clinical study of NASARIX.

The study enrolled participants across five U.S. clinical research sites after screening 144 individuals. The randomized, controlled study compares the investigational nasal hydrogel with a saline control in adults with allergic rhinitis, assessing its performance in managing associated symptoms. NASARIX uses Capture and Contain technology to form a barrier within the nasal cavity designed to limit allergen contact with the nasal lining.

Polyrizon expects to proceed with data review and analysis under the study protocol after completing treatment and follow-up periods. Enrollment completion is a development milestone, not a clinical performance result.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
-
Rhea-AI Summary

Polyrizon (PLRZ) has filed a new U.S. divisional patent application covering aspects of its intranasal drug-delivery technology. The application, titled “Mucoadhesive Polymers for Nasal Drug Delivery,” was assigned number 19/823,285 by the United States Patent and Trademark Office. A divisional application seeks separate protection for aspects of an existing patent family.

The filing concerns polymers that adhere to mucosal tissue. Polyrizon views the technology as a potential platform for delivering therapeutic agents locally or systemically through nasal tissue. It continues developing the technology for stand-alone intranasal products and potential drug-delivery applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
none
Rhea-AI Summary

Polyrizon (PLRZ) has enrolled the first patient in its U.S. clinical study of NASARIX (PL-14), an investigational, non-drug Allergy Blocker for seasonal allergic rhinitis. This milestone moves Polyrizon into the clinical-stage of development and marks the first-in-human evaluation of NASARIX.

NASARIX is a mucoadhesive hydrogel nasal spray designed to form a physical barrier in the nasal cavity, limiting contact between inhaled airborne allergens and the nasal mucosa to help alleviate allergy symptoms. The prospective, multicenter, randomized, single-blind, two-arm study will enroll about 120 adult patients across 5 U.S. clinical sites, randomized 1:1 to receive NASARIX or a saline nasal spray comparator.

The trial will assess efficacy, safety and tolerability. The primary endpoint is the difference in mean daily reflective Total Nasal Symptom Score (rTNSS) between PL-14 and saline over the first 14 treatment days, alongside monitoring of treatment-emergent adverse events and local/overall tolerability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.20%
Tags
-
Rhea-AI Summary

Polyrizon (PLRZ) closed its previously announced registered direct offering and concurrent private placement raising approximately $4.0 million in aggregate gross proceeds from a single institutional investor.

The company sold 333,333 Units/Pre-Funded Units, each comprising one Ordinary Share (or one Pre-Funded Warrant for one Ordinary Share) and one Common Warrant, at a combined offering price of $12.00 per Unit (or $11.99999 per Pre-Funded Unit). In the registered direct deal, Polyrizon issued 232,500 Ordinary Shares and 30,000 Pre-Funded Warrants, and in the private placement it issued 70,833 PIPE Pre-Funded Warrants and 333,333 PIPE Common Warrants with an exercise price of $12.00 per share. The transactions closed on September 4, 2026, and the company expects to use the net proceeds for general corporate purposes and working capital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.51%
Tags
private placement offering
-
Rhea-AI Summary

Polyrizon (PLRZ) entered definitive agreements on September 3, 2026 for a registered direct offering and concurrent private placement totaling approximately $4.0 million with a single institutional investor.

The financing involves 333,333 Units (or Pre-Funded Units), each with one Ordinary Share (or one Pre-Funded Warrant) and one Common Warrant, at $12.00 per Unit ($11.99999 per Pre-Funded Unit). The registered direct portion covers 232,500 Ordinary Shares and 30,000 Pre-Funded Warrants, while the private placement adds 70,833 PIPE Pre-Funded Warrants and 333,333 PIPE Common Warrants, all with a $12.00 exercise price for the Common Warrants. Closing is expected on or about September 4, 2026, subject to customary conditions. Net proceeds, together with existing cash, are expected to fund general corporate purposes and working capital. After completion, assuming full exercise of all Pre-Funded Warrants, Polyrizon will have 2,806,233 Ordinary Shares outstanding.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.40%
Tags
private placement offering
Rhea-AI Summary

Polyrizon (PLRZ) has completed contracting with all five U.S. clinical sites for its first-in-human study of NASARIX™ Allergy Blocker (PL-14), advancing the program into study execution.

The prospective, multicenter, randomized, single-blind, two-arm trial in seasonal allergic rhinitis will enroll up to 120 patients, randomized 1:1 to receive NASARIX or an isotonic saline nasal spray control. The primary efficacy endpoint is the difference between treatment groups in mean daily reflective Total Nasal Symptom Score (rTNSS) over the first 14 treatment days, with safety assessed via treatment-emergent adverse events and local/overall tolerability. Secondary measures are expected to include instantaneous TNSS (iTNSS), quality of life, symptom-free days, and use of permitted relief medication. Enrollment is planned to align with relevant allergy seasons, using local pollen counts and weather conditions to guide recruitment timing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.88%
Tags
none
-
Rhea-AI Summary

Polyrizon (Nasdaq: PLRZ) announced completion of contracting with all five U.S. clinical sites selected for its first-in-human study of NASARIX™ Allergy Blocker (PL-14), an intranasal hydrogel-based product for seasonal allergic rhinitis. This operational milestone enables progression from clinical preparation toward execution.

The prospective, multicenter, randomized, single-blind, two-arm trial is designed to enroll up to 120 patients, randomized 1:1 to NASARIX or isotonic saline nasal spray. The primary endpoint is mean daily reflective Total Nasal Symptom Score over the first 14 treatment days, with additional safety, tolerability and quality-of-life assessments. Polyrizon is initiating patient pre-screening and preparing enrollment to coincide with relevant allergy seasons.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.26%
Tags
none
-
Rhea-AI Summary

Polyrizon (Nasdaq: PLRZ) reported successful completion of the biocompatibility evaluation program for its NASARIX™ Allergy Blocker nasal spray, with all required biological safety tests meeting predefined acceptance criteria.

The ISO 10993- and FDA-guided program strengthens the non-clinical safety package and supports advancement toward a first-in-human clinical trial and potential commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.83%
Tags
Rhea-AI Summary

Polyrizon (Nasdaq: PLRZ) received central IRB approval from BRANY on June 18, 2026 to begin its first human clinical trial of NASARIX™, a nasal spray allergy blocker. The approved study will compare NASARIX to saline in patients with seasonal allergic rhinitis, assessing efficacy, safety, tolerability, and quality-of-life outcomes. The master protocol approval is valid through June 17, 2027, while each clinical site must still secure its own site-specific IRB approval before activating sites and enrolling participants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.06%
Tags

FAQ

What is the current stock price of Polyrizon (PLRZ)?

Polyrizon (PLRZ) last closed at $11.05.

What is the market cap of Polyrizon (PLRZ)?

The market cap of Polyrizon (PLRZ) is approximately $26.8M.